Notice ID: 82f31e6bd3874580a6f43290aa33fa41Award NoticeAwarded
BARDA Radiological and Nuclear (RADNUC) Animal Model and Medical Countermeasures (MCM) Development
Awarded on September 7, 2022. Full description on SAM.gov.
Awarded tounder 75A50122D00016 (source: SAM.gov award notice)• $75.0K
Overview
- Posted
- September 19, 2022
- Notice type
- Award Notice
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of Health and Human Services
Notice details
- Last updated
- Dec 4, 2025
- Award date
- Sep 7, 2022
- Award amount (SAM.gov award notice)
- $75.0K
Identifiers
- Solicitation number
- 75A50121R00017
- Notice ID
- 82f31e6bd3874580a6f43290aa33fa41
- Award number (PIID)
- 75A50122D00016
Description
The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), seeks appropriate Good Laboratory Practices (GLP) facilities that are adequate and available to establish new or use existing animal models for the development of radiological and nuclear MCMs. In these models, the radiation exposure should be comparable to that which produces the human disease or condition and the pathophysiological mechanism of its toxicity should be reasonably well-understood and mimic the human disease/condition as closely as possible. These models will be used to test the efficacy of potential RadNuc MCMs. The mechanism of action of the countermeasure will also need to establish the utility of the animal model as a surrogate for humans. Laboratories must meet the following mandatory eligibility criteria to be considered: Evidence of Federal, State, and/or local licenses as required for the operation and control of a clinical level irradiation facility with qualified personnel for the operation, assigned safety restrictions, domestic and instrument calibration per licensed Health Physics authority. Evidence of Federal, State, and/or local licenses as required for the storage, use, and disposal of select agents such as chemical agents and radionuclides and training of all associated staff responsible for the use of such material. Evidence of accreditation or licensure of the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accreditation or equivalent. Evidence of U.S. Department of Agriculture (USDA) animal research facility license, or equivalent. Completion of at least one good laboratory practice (GLP) study. Evidence of capability to conduct either small or large (or both) animal model studies. Provided plan for conducting studies in two animal models, with at least one being a large animal model. Subcontracting is an available option to expand capabilities. HHS, through the interagency Public Health Emergency and Medical Countermeasure Enterprise (PHEMCE) is responsible for the integration of requirements for the advanced development and procurement of MCMs for CBRN threats specified by the Department of Homeland Security as material threats. The HHS PHEMCE Strategy for Chemical, Biological, Radiological, and Nuclear Threats (HHS PHEMCE Strategy), published in the Federal Register on March 20, 2007 describes the strategic policy goals and objectives for identifying requirements and establishes the priorities for the development of the MCMs. The HHS PHEMCE Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats (HHS PHEMCE Implementation Plan), published in the Federal Register on April 2007 with subsequent updates between December 2012 and 2017, delineates HHS MCM priorities for research, development and acquisition to address the highest priority CBRN threats. The development of animal models is a key element in the development of MCM for CBRN threats, particularly since efficacy of products against most of these threats cannot be verified using human clinical studies. In 2002 and 2015, the FDA amended its regulations for drugs and biologics to permit approval or licensure of medical countermeasures based on substantial evidence of effectiveness in animals when adequate and well-controlled efficacy studies in humans cannot be conducted because it would be unethical to expose healthy human volunteers to lethal or disabling toxic CBRN substances, and relevant field efficacy trials in humans are not feasible. This change in the regulations (21 CFR 314.600 for drugs and 21 CFR 601.90 for biologics), commonly referred to as the Animal Rule, made the design and conduct of adequate efficacy studies in appropriate animal models of paramount regulatory importance, since the inference of efficacy in humans is based on efficacy data derived in animals. The primary demonstration of safety of the MCM (drug or biologic) is conducted in human clinical studies, although non-clinical data will also be used to evaluate safety.
Award Overview
Award Number
75A50122D00016
Award Amount (SAM.gov award notice)
$75.0K
Award Date
Sep 7, 2022
Awardee
Awardee UEI
Z9CRZKD42ZT1
Awardee CAGE Code
1B0S2
Original Solicitation
Notice ID: 82f31e6bd3874580a6f43290aa33fa41
Posted Date: Sep 19, 2022
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $8.4MSigned Aug 4, 2026
- $7.6MSigned Apr 10, 2026
- $7.6MSigned Dec 16, 2025
- $7.6MSigned Sep 18, 2025
- $7.6MSigned Oct 9, 2025
- $3.7MSigned Apr 17, 2024
- $3.7MSigned Sep 27, 2023
- $3.7MSigned Jul 25, 2025
- $3.7MSigned Jan 8, 2025
- $3.7MSigned Sep 12, 2024
More From This Vendor
Top 5 most recent
- $6.0MSigned Oct 27, 2026
- $3.0MSigned Aug 6, 2026
- $8.4MSigned Aug 4, 2026
- $3.0MSigned May 14, 2026
- $7.6MSigned Apr 10, 2026
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75A50121R00017- Pre-Solicitation
- Solicitation
- Awarded
This opportunity has been awarded.
- Pre-SolicitationFeb 1, 2021
BARDA Radiological and Nuclear (RADNUC) Animal Model and Medical Countermeasures (MCM) Development
- 2×SolicitationOct 13, 2021
BARDA Radiological and Nuclear (RADNUC) Animal Model and Medical Countermeasures (MCM) Development
- 4×AwardedCurrentSep 19, 2022
BARDA Radiological and Nuclear (RADNUC) Animal Model and Medical Countermeasures (MCM) Development
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Advanced Research Projects Agency for Health (ARPA-H) posts this Special Notice in support of its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) Program. Interested parties are invited to review the attached Notice related to an informational webinar on 15 OCT 2026 and a 2-day Proposers’ Day on 6 and 9 NOV 2026 in support of SURPASS. For more information related to the SURPASS opportunity, see solicitation ARPA-H-SOL-26-164. All questions related to SURPASS should be submitted to SURPASS@ARPA-H.GOV. | - | Special Notice | 10/12/2026 |
The Advanced Research Projects Agency for Health (ARPA-H) posts this solicitation in support of its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) Program. ARPA-H anticipates multiple Other Transaction Agreement awards will result from this opportunity. Interested parties are invited to review the attached Solicitation (ARPA-H-SOL-26-164) and associated attachments. As detailed in Special Notice ARPA-H-SN-26-164, ARPA-H will host an informational webinar on 15 OCT 2026 and a 2-day Proposers’ Day on 6 and 9 NOV 2026 in support of SURPASS. All questions related to SURPASS should be submitted to SURPASS@ARPA-H.GOV. | - | Solicitation | 11/30/2026 |
Amendment 01: The Proposers' Day has been updated to October 16th, 2026. The Advanced Research Projects Agency for Health (ARPA-H) is posting this Innovative Solutions Opening (ISO) in support of the UNifying Imaging with QUantum Entanglement (UNIQUE) Program. ARPA-H anticipates that multiple Other Transaction (OT) Agreements will result from this announcement. Interested parties are invited to review the attached UNIQUE-ISO-ARPA-H-SOL-26-162 and UNIQUE ISO Attachments. Additionally, proposers are encouraged to review the separate Special Notice, ARPA-H-SN-26-162, for information regarding the UNIQUE Proposers’ Day. Special Notice, ARPA-H-SN-26-162, is an independent announcement and is not attached to this ISO announcement. All questions submitted to the ISO will be compiled and addressed. All answers will be posted to the UNIQUE Frequently Asked Questions (FAQ) page. Potential proposers are encouraged to monitor the FAQs page regularly for the latest information and updates: https://arpa-h.gov/explore-funding/programs/unique/faqs | - | Solicitation | 12/15/2026 |
We appreciate your interest in partnering with BARDA. The latest BARDA Broad Agency Announcement (BAA) is Amendment 7 posted on March 19, 2026. All contracting-related inquiries should be sent to BARDA-BAA@hhs.gov. The final proposal submission deadline is September 25, 2028, at 4:30 PM Eastern Time for open areas of interest. | - | Solicitation | 09/25/2028 |
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/. _______ Amendment 001: This amendment to the EZBAA hereby opens the following research areas of interest ("AOI"). Please review the amendment for details of each AOI, including closing dates: AOI #15: ReDIRECT AOI #16: Lab at Home AOI #17: Digital MCMs AOI #18: Host-Directed Therapeutics AOI #19: Healing Lungs AOI #20: DRIVe Forward AOI #21: Vaccines on Demand AOI #22: ReBooT AOI #23: Host-Based Diagnostics _____ 11/8/22 - Please see Amendment 002 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the the following Area of Interest (AOI): AOI #24: REPAIR 2. Clarifying an adminstrative error. _____ 11/14/22 - Please see Amendment 003 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Revising the following Area of Interest (AOI): AOI #19: Healing Lungs _____ 12/15/22 - Please see Amendment 004 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #21: Vaccines on Demand ______ 1/11/23 - Please see Amendment 005 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI) by establishing a new closing date of February 15, 2023 at 12:00PM ET: AOI #15: ReDIRECT ______ 2/1/23 - Please see Amendment 006 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 2. Updating the closing date for the following Area of Interest (AOI): AOI #17: Digital MCMs 3. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 4. Revising the following Area of Interest (AOI): AOI #16: Lab at Home ______ 2/3/23 - Please see Amendment 007 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #24: REPAIR ______ 5/1/23 - Please see Amendment 008 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #25: FASTx 2. Updating the language in Section III (F) of the Easy Broad Agency Announcement titled “Plus (+) Phase”. ______ 5/18/23 - Please see Amendment 009 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI), which is reopened to support project Next Gen: AOI #21: Vaccines on Demand ______ 5/25/23 - Please see Amendment 010 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Revising the following Area of Interest (AOI): AOI #24: REPAIR 2. Updating the closing date for the following Area of Interest (AOI): AOI #24: REPAIR ______ 6/27/23 - Please see Amendment 011 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Closing the following Area of Interest (AOI): AOI #18: Host-Directed Therapeutics 2. Closing the following Area of Interest (AOI): AOI #23: Host-Based Diagnostics 3. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs ______ 9/13/23 - Please see Amendment 012 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #17: Digital MCMs 3. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 4. Revising the following Area of Interest (AOI): AOI #16 Lab at Home 5. Adding the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic _______ 9/14/23 - Please see Amendment 013 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #20: DRIVe Forward ________ 9/26/23 - Please see Amendment 014 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #21: Vaccines on Demand _________ 10/26/23 - Please see Amendment 015 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #22: ReBoot 2. Updating the closing date for the following Area of Interest (AOI): AOI #25: FASTx 3. Revising the following Area of Interest (AOI): AOI #22: ReBoot 4. Revising the following Area of Interest (AOI): AOI #25: FASTx ___________ 10/30/23 - Please see Amendment 016 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #24: REPAIR __________ 11/15/23 - Please see Amendment 017 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #20: DRIVe Forward 2. Revising the following Area of Interest (AOI): AOI #20: DRIVe Forward __________ 12/13/23 - Please see Amendment 018 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Revising the following Area of Interest (AOI): AOI #16: Lab at Home 3. Pausing the following Area of Interest (AOI): AOI #17: Digital MCMs 4. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs __________ 01/03/24 - Please see Amendment 019 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #15: ReDIRECT 2. Revising the following Area of Interest (AOI): AOI #15: ReDIRECT __________ 01/10/24 - Please see Amendment 020 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic 2. Adding a topic to the following Area of Interest (AOI): AOI #20: DRIVe Forward 3. Updating the closing date for the following Area of Interest (AOI): AOI #20: DRIVe Forward _________ 01/18/24 - Please see Amendment 021 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #27: Stopping Secondary Spread __________ 2/5/24 - Please see Amendment 022 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following research Area of Interest (AOI): AOI #27: Stopping Secondary Spread 2. Revise topics for the following research Area of Interest (AOI): AOI #20: DRIVe Forward __________ 02/12/24 - Please see Amendment 023 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic __________ 02/21/24 - Please see Amendment 024 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #22: ReBooT 2. Updating the closing date for the following Area of Interest (AOI): AOI #25: FASTx __________ 03/04/24 - Please see Amendment 025 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #24: RePAIR 2. Revising the following Area of Interest (AOI): AOI #24: RePAIR __________ 03/12/24 - Please see Amendment 026 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs _________ 04/22/24 - Please see Amendment 027 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #20: DRIVe Forward 2. Removing two topic areas and adding one topic area to the following Area of Interest (AOI): AOI #20: DRIVe Forward _________ 05/01/24 - Please see Amendment 028 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #15: ReDIRECT 2. Updating the closing date for the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic 3. Reopening the following Area of Interest (AOI): AOI #17: Digital MCMs 4. Revising the following Area of Interest (AOI): AOI #17: Digital MCMs __________ 05/09/24 - Please see Amendment 029 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 3. Revising the following Area of Interest (AOI): AOI #19: Healing Lungs 4. Updating the closing date for the following Area of Interest (AOI): AOI #24: RePAIR _________ 09/24/24 - Please see Amendment 030 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #28: Influenza Vaccine Innovation 2. Pausing the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic ___________ 09/30/24 - Please see Amendment 031 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #24: RePAIR ___________ 10/10/24 - Please see Amendment 032 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Update the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs Pause the following Area of Interest (AOI) on 10/31/24: AOI #17: Digital MCMs ___________ 10/31/24 - Please see Amendment 033 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Reopen the following Area of Interest (AOI) on 11/1/24: AOI #15: ReDIRECT 2. Remove language requiring a Rough Order of Magnitude (ROM) from the record 11/26/2024 - Please see Amendment 034 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1) Reopen the following Area of Interest (AOI): AOI #22: ReBooT 2) Revise the following Area of Interest (AOI): AOI #22: ReBooT 3) Pause the following Area of Interest (AOI): AOI#24: RePAIR ___________ 1/13/2025 - Please see Amendment 035 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1) Reopen the following Area of Interest (AOI) on 1/15/2025: AOI #16: Lab at Home 2) Open the following Area of Interest (AOI): AOI #29: Type to Treat ___________ 2/14/2025 - Please see Amendment 036 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lung __________ 4/22/2025 - Please see Amendment 037 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this amendment, BARDA is revising the following Areas of Interest (AOI) to close effective immediately: AOI #19: Healing Lungs AOI #22: ReBooT AOI #29: Type to Treat Additional details can be found in the corresponding Amendment 037. | - | Solicitation | 10/18/2027 |
Additional Details
Solicitation Number
75A50121R00017
Archive Date
Oct 3, 2022
Office Address
WASHINGTON, DC, 20515